Why vaccines may fail in older adults: new study investigates immune cell role

NCT ID NCT06128915

Recruiting now Knowledge-focused Sponsor: State University of New York at Buffalo Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how a type of immune cell called neutrophils affects the body's response to the pneumococcal vaccine in young (21-40) and older (65+) adults. Researchers will measure how well neutrophils kill pneumonia bacteria after vaccination. The goal is to understand why vaccine responses decline with age, which could help improve vaccines for older populations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pneumococcal vaccine (20 serotypes)
What this could lead to: If successful, this could explain why older adults respond less to vaccines and point toward ways to improve vaccine effectiveness in the elderly.
What could go wrong: This is a small, early-stage observational study (60 participants) that measures immune cell activity, not clinical outcomes. It may not lead to any direct treatment or vaccine changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGING

Contacts and locations

Locations

University at Buffalo
RECRUITING

Buffalo, New York, 14203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.